Trastuzumab
- Generic Name
- Trastuzumab
- Brand Names
- Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ontruzant, Perjeta-Herceptin, Phesgo, Trazimera, Herwenda, Ogivri, Zercepac, Tuznue
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 180288-69-1
- Unique Ingredient Identifier
- P188ANX8CK
- Background
Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic bre...
- Indication
For the adjuvant treatment of HER2-overexpressing breast cancer, trastuzumab is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; as part of a treatment regimen with docetaxel and carboplatin; or as monotherapy following multi-modality anthracycline-based th...
- Associated Conditions
- Breast Cancer, Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Adenocarcinoma of the Stomach, Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage I Breast Cancer
- Associated Therapies
- -
TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Reva Basho
- Registration Number
- NCT04512261
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
- Conditions
- Interventions
- First Posted Date
- 2020-08-12
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT04510285
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack, New York, United States
Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer
- First Posted Date
- 2020-08-05
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT04499924
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
- Conditions
- Interventions
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- NKGen Biotech, Inc.
- Registration Number
- NCT04464967
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04430738
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇯🇵National Cancer Center Hospital, Chuo-ku, Other, Japan
MARGetuximab Or Trastuzumab (MARGOT)
- Conditions
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 174
- Registration Number
- NCT04425018
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Dana-Farber Brigham Cancer Center - Foxborough, Foxboro, Massachusetts, United States
Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 20
- Registration Number
- NCT04419181
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 216
- Registration Number
- NCT04398914
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
- First Posted Date
- 2020-05-07
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 413
- Registration Number
- NCT04379596
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2020-04-08
- Target Recruit Count
- 493
- Registration Number
- NCT04337658
- Locations
- 🇨🇳
Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.